Searched for
DR REDDYS LABORATORIES
Andhra man quits pharmaceutical industry after 25 years to grow Moringa. Turns leaves into a Rs 1,000/Kg product, earns Rs 15 lakh per acreAfter dedicating 25 years of his career to Dr Reddy's Laboratories, Annapureddy Prakash Reddy took a bold step back to his agricultural roo...- DRL, Emcure get approval to make breakthrough HIV drugIndia's drug regulator has cleared the path for local lenacapavir manufacturing. Two Indian pharmaceutical companies received waivers for l...
- Indian pharma has little reason to fear TrumpUS tariff threats on Indian generic drugs face significant obstacles. These duties could increase American healthcare costs and potentially...
- Tata Steel, Adani Ports among top 10 stocks downgraded by Motilal Oswal after Q1 results
- GLP-1 drugs create new market for collagen, protein and beauty products in IndiaThe rising use of GLP-1 weight-loss drugs such as Ozempic and Mounjaro is creating a new consumer market in India, with companies developin...
- From gut bacteria to the brain, a chemical, sodium butyrate traveled through the bloodstream after traumatic injury, where 4 months of treatment helped scientists reduce inflammation, protect brain cells and made seizures less frequentPost-traumatic epilepsy treatment: Researchers are exploring sodium butyrate to prevent post-traumatic epilepsy after brain injuries. This ...
- Max Healthcare among 4 F&O stocks with sharp rise in futures OIA significant uptick in futures open interest indicates substantial growth in the number of active, unexpired futures contracts in a specif...
- Picture perfect quarter? Nifty profit growth hits a 10-quarter high, but 5 stocks do the heavy liftingNifty firms have recorded their most impressive profit growth in a decade, boasting significant contributions from five leading companies, ...
- Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEOGland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to h...
- Parag Parikh Flexi Cap Fund hikes stakes in HCL Tech, Coal India and 9 other stocks in July. Check full listParag Parikh Flexi Cap Fund, the largest active flexicap fund by AUM, raised its stake in HCL Technologies, Coal India and nine other stock...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Uzbekistan invites Indian firms for mining, minerals push ahead of PM Modi's visitIn a bid to enhance economic ties, Uzbekistan is inviting Indian investments into its mining and metallurgy sectors, highlighting lucrative...
- Dr Reddy's Laboratories launches generic Sugammadex injection in the United StatesDr Reddy's Laboratories has launched its generic Sugammadex injection in the United States. This new product reverses muscle relaxant effec...
- Nifty Q1 earnings grow 11% to beat estimate, says Motilal Oswal; picks Bharti Airtel, SBI, ICICI Bank among top betsNifty companies have posted a stronger-than-expected start to Q1 earnings, with profits of 39 reporting constituents rising 11% YoY, beatin...
- FIIs cut stakes in 72% of Nifty50 stocks, DIIs buy 82%. Here’s where the money movedIndia’s largest stocks are witnessing a major ownership shift as domestic institutions fill the gap left by foreign investors. FIIs cut sta...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Stocks in news: Infosys, Cipla, Meesho, Suzlon Energy, IndiGo, NTPCMarkets extended their losing streak for a fourth consecutive session. Infosys reported a 12% year-on-year profit growth in its first quart...
- Buy, Sell or Hold? Goldman Sachs maintains a buy on Eternal; Citi recommends sell rating on Dr Reddy’s Laboratories post Q1 resultsGoldman Sachs and Citi have issued fresh post-Q1 calls on three stocks. Goldman stays bullish on Eternal (Buy, target Rs 345, 21% upside) d...
- Tariff hike by US will only increase drug prices: Dr Reddy's CEOUS tariff increases on generic medicines will lead to higher drug prices in India. Dr Reddy's Laboratories CEO Erez Israeli stated relocati...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
Load More
